We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.
The Zacks Consensus Estimate for revenues is pegged at $6.44 billion, which indicates an increase of 0.5% from the year-ago quarter’s figure. The consensus mark for earnings is pinned at $2.16 per share, which increased a penny in the past 60 days. The estimate indicates an increase of 3.4% from the figure reported in the year-ago quarter. The company’s bottom line surpassed the Zacks Consensus Estimate by 9.6% in the last reported quarter. It has a trailing four-quarter earnings surprise of 10.2%, on average.
Let’s see how things have shaped up for Danaher this earnings season.
Weakness in Danaher’s Instrument businesses, due to lower demand across pharma and biotech markets in China, is likely to have hurt the Life Sciences segment’s revenues in the fourth quarter. Also, sales decline in mass spectrometry, flow cytometry & lab automation solutions, and microscopy businesses due to soft demand for equipment in the major end-markets is likely to have ailed the segment. We expect the segment’s organic revenues to decrease 2.6% year over year in the fourth quarter.
Danaher’s Biotechnology segment is expected to have been hurt by decreased demand in the discovery and medical business.
DHR has been witnessing escalating SG&A expenses, which are likely to weigh on its bottom-line results. We expect SG&A expenses to be $2.1 billion, indicating an increase of 3.2% year over year.
The company has considerable exposure to overseas markets. Given its substantial international operations, foreign currency headwinds are likely to have marred its profitability.
We expect the company’s revenues to be $6.4 billion, indicating a decrease of 0.2% year over year.
However, strength in the clinical diagnostics business, driven by growth in Leica Biosystems and Beckman Colter Diagnostics units, is expected to have aided the Diagnostics segment. The segment’s performance is also likely to have gained from strong momentum in the clinical diagnostics businesses and solid growth in the molecular diagnostics business.
Danaher acquired Abcam plc, a global supplier of protein consumables, in December 2023, which expanded the Life Sciences segment. Abcam's long track record of innovation, outstanding product quality and breadth of antibody portfolio are expected to have helped Danaher solve some pertaining healthcare challenges.
We expect the company’s adjusted earnings to be $2.14 per share, indicating an increase of 2.3% year over year.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for DHR this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as elaborated below.
Earnings ESP: Danaher has an Earnings ESP of +0.96% as the Most Accurate Estimate is pegged at $2.18 per share, which is higher than the Zacks Consensus Estimate of $2.16. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.
Zacks Rank: Danaher presently carries a Zacks Rank #4 (Sell).
Stocks to Consider
Here are some companies, which according to our model, have the right combination of elements to beat on earnings in this reporting cycle.
The company is slated to release third-quarter fiscal 2025 (ended December 2024) results on Feb. 5. EnerSys’ earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 1.7%.
Dover Corporation (DOV - Free Report) has an Earnings ESP of +0.10% and a Zacks Rank of 3 at present. The company is scheduled to release fourth-quarter 2024 results on Jan. 30.
Dover’s earnings surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 4%.
AptarGroup, Inc. (ATR - Free Report) has an Earnings ESP of +0.16% and a Zacks Rank of 3 at present. The company is slated to release fourth-quarter 2024 results on Feb. 6.
AptarGroup’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 6.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Danaher Gears Up to Post Q4 Earnings: What Lies Ahead for the Stock?
Danaher Corporation (DHR - Free Report) is scheduled to release fourth-quarter 2024 results on Jan. 29, before market open.
Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.
The Zacks Consensus Estimate for revenues is pegged at $6.44 billion, which indicates an increase of 0.5% from the year-ago quarter’s figure. The consensus mark for earnings is pinned at $2.16 per share, which increased a penny in the past 60 days. The estimate indicates an increase of 3.4% from the figure reported in the year-ago quarter. The company’s bottom line surpassed the Zacks Consensus Estimate by 9.6% in the last reported quarter. It has a trailing four-quarter earnings surprise of 10.2%, on average.
Let’s see how things have shaped up for Danaher this earnings season.
Danaher Corporation Price and EPS Surprise
Danaher Corporation price-eps-surprise | Danaher Corporation Quote
Key Factors and Estimates for Q4
Weakness in Danaher’s Instrument businesses, due to lower demand across pharma and biotech markets in China, is likely to have hurt the Life Sciences segment’s revenues in the fourth quarter. Also, sales decline in mass spectrometry, flow cytometry & lab automation solutions, and microscopy businesses due to soft demand for equipment in the major end-markets is likely to have ailed the segment. We expect the segment’s organic revenues to decrease 2.6% year over year in the fourth quarter.
Danaher’s Biotechnology segment is expected to have been hurt by decreased demand in the discovery and medical business.
DHR has been witnessing escalating SG&A expenses, which are likely to weigh on its bottom-line results. We expect SG&A expenses to be $2.1 billion, indicating an increase of 3.2% year over year.
The company has considerable exposure to overseas markets. Given its substantial international operations, foreign currency headwinds are likely to have marred its profitability.
We expect the company’s revenues to be $6.4 billion, indicating a decrease of 0.2% year over year.
However, strength in the clinical diagnostics business, driven by growth in Leica Biosystems and Beckman Colter Diagnostics units, is expected to have aided the Diagnostics segment. The segment’s performance is also likely to have gained from strong momentum in the clinical diagnostics businesses and solid growth in the molecular diagnostics business.
Danaher acquired Abcam plc, a global supplier of protein consumables, in December 2023, which expanded the Life Sciences segment. Abcam's long track record of innovation, outstanding product quality and breadth of antibody portfolio are expected to have helped Danaher solve some pertaining healthcare challenges.
We expect the company’s adjusted earnings to be $2.14 per share, indicating an increase of 2.3% year over year.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for DHR this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as elaborated below.
Earnings ESP: Danaher has an Earnings ESP of +0.96% as the Most Accurate Estimate is pegged at $2.18 per share, which is higher than the Zacks Consensus Estimate of $2.16. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.
Zacks Rank: Danaher presently carries a Zacks Rank #4 (Sell).
Stocks to Consider
Here are some companies, which according to our model, have the right combination of elements to beat on earnings in this reporting cycle.
EnerSys (ENS - Free Report) has an Earnings ESP of +7.24% and a Zacks Rank of 2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The company is slated to release third-quarter fiscal 2025 (ended December 2024) results on Feb. 5. EnerSys’ earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 1.7%.
Dover Corporation (DOV - Free Report) has an Earnings ESP of +0.10% and a Zacks Rank of 3 at present. The company is scheduled to release fourth-quarter 2024 results on Jan. 30.
Dover’s earnings surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 4%.
AptarGroup, Inc. (ATR - Free Report) has an Earnings ESP of +0.16% and a Zacks Rank of 3 at present. The company is slated to release fourth-quarter 2024 results on Feb. 6.
AptarGroup’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 6.1%.